GSK and Hitachi Chemical Signs a Three-year Agreement for T-cell Therapy

 GSK and Hitachi Chemical Signs a Three-year Agreement for T-cell Therapy

GSK and Hitachi Chemical Signs a Three-year Agreement for T-cell Therapy

Shots:

  • Hitachi Chemical’s subsidiary HCATS (Hitachi Chemical Advanced Therapeutics Solutions), will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials
  • The agreement focuses on providing, compliant, flexible, scalable, and cost-effective therapies accessible to cancer patients
  • NY-ESO-1 is a human tumor antigen expressed in sarcomas, melanoma, multiple myeloma, bladder cancer, NSCLC, ovarian cancer and gastro-intestinal cancers

Click here to read full press release/ article | Ref: Businesswire | Image: CNBC

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post